The Safety And Efficacy Of Riociguat Treatment In The Management Of Pulmonary Arterial Hypertension
Objective The soluble form of guanylate cyclase (sGC) stimulator riociguat has been approved for the management of patients with PAH (pulmonary arterial hypertension). It is also approved for the treatment of inoperable or recurrent/persistent chronic thromboembolic pulmonary hypertension after its safety and efficacy were assessed during the phase 3 randomized trials. This EXPERT (EXPosurE Registry RiociguaT) study in patients with pulmonary hypertension is designed to assess the long-term safety of this medication in clinical practice. Methods EXPERT is an international, non-interventional prospective, multicenter, uncontrolled, cohort study of patients who were administered riociguat. During this study, patients were followed up for at least one year and up to four years from the enrollment or for 30 days after they stopped riociguat treatment. The safety outcomes were related to the serious adverse events (SAEs) and adverse events (AEs) coded using Medical Dictionary for the Sy